Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43515 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5980862 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5605868 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2652715 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL503347 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL123134 | 1.00 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL971796 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Water SCHEMBL2651079 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Water SCHEMBL29155398 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL971795 | 0.98 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765763-B2 | Substituted piperazines as CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8568689-B1 | uPAR-targeting contrast agents | GE HEALTHCARE AS (NO) | 2013-10-29 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-1796733-A2 | UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED CONTRAST AGENTS | GE Healthcare AS (NO) | 2007-06-20 | — | — | EP | disclosed |
| EP-1425009-A4 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX INST FOR DRUG RES LTD (HU) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006036071-A2 | UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED CONTRAST AGENT | GE HEALTHCARE AS (NO) | 2006-04-06 | — | — | WO | disclosed |
| EP-1349856-B1 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2005-03-31 | — | — | US | disclosed |
| EP-1425009-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | Ivax Institute for Drug Research, Ltd. (HU) | 2004-06-09 | — | — | EP | disclosed |
| EP-1349856-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003016273-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6482951-B2 | ISOINDOLIN-1-ONE-SUBSTITUTED PROPIONAMIDE GLUCOKINASE ACTIVATORS WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GUERTIN KEVIN RICHARD (US) | 2002-06-27 | — | — | US | disclosed |
| WO-2002048106-A2 | ISOINDOLIN-1-ONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| US-4914129-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4889869-A | ANTIALDOSTERONISM AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0236734-A2 | 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082260-A1 | Isoindolin-1-one glucokinase activators | GCKR, GCK, PGK2 | GRIN2D 2231/4885GRIN3B 2515/4885GRIN1 1803/4885 |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | CALCR, CALCRL, P2RX5 | GRIN2D 615/4885GRIN3B 378/4885GRIN1 275/4885 |
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | ARGLU1, PLAT, SERPINC1 | GRIN2D 4478/4885GRIN3B 2648/4885GRIN1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.